Methods and compositions for improving in vivo survival of midbrain dopamine neurons
AssigneesMemorial Sloan Kettering Cancer Center, Sloan-Kettering Institute for Cancer Research, Memorial Hospital for Cancer and Allied Diseases
InventorsLorenz Studer, Taewan Kim, So Yeon Koo
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for improving in vivo survival of midbrain dopamine (mDA) neurons (e.g., in vitro differentiated mDA neurons) by suppressing p53-mediated apoptosis of mDA neurons. The present disclosure further provides methods for treating a subject (e.g., a subject suffering from neurodegeneration of midbrain dopamine neurons, and/or a neurodegenerative disease), comprising administering to the subject one or more mDAs, wherein p53-mediated apoptosis of the one or more mDA neurons is suppressed.
Claims20
A method for treating a subject, comprising administering to the subject one or more midbrain dopamine (mDA) neurons, wherein p53-mediated apoptosis of the one or more mDA neurons is suppressed.
A method of improving in vivo survival of one or more midbrain dopamine (mDA) neurons, comprising suppressing p53-mediated apoptosis of the one or more mDA neurons.
A composition comprising:
- (a) one or more midbrain dopamine (mDA) neurons;
- and
- (b) at least one compound selected from the group consisting of TNFα inhibitors, NFκB inhibitors, p53 inhibitors, and combinations thereof.
Dependencies are inferred from the claim text.